Statins May Reduce Risk of Venous Thromboembolism in Women Taking Hormone Therapy: A Case-Control Study of 250,000 Women Aged 50-64

John W. Davis, BA¹ Susan C. Weller, PhD^{1,2} Laura Porterfield, MD^{2,3} Lu Chen, MS¹ Gregg Wilkinson, PhD¹

 Department of Population Health Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, TX
Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX
Department of Family Medicine, School of Medicine, University of Texas Medical Branch, Galveston, TX

> Corresponding Author: Susan C. Weller Dept Population Health Science School of Public and Population Health University of Texas Medical Branch 300 Harborside Dr. Galveston, Tx 77555-1153

Email: sweller@utmb.edu Phone: 409-772-2551 Competing Interests: None declared. Funding: The data were obtained with a grant to SCW from the Texas Academy of Family Physicians Foundation (Austin, Texas).

ABSTRACT (words: 249 abstract; text 2,951)

Importance. Post-menopausal hormone therapy (HT) may elevate the risk of venous thromboembolism (VTE), while statin therapy may lower risk.

Objective To estimate VTE risk from HT exposure with statin therapy in women 50-64 years of age.

Design, Setting, Participants, Exposure & Outcomes. A case-control study in a large commercially-insured database matched cases of VTE diagnoses (1:10) to controls without VTE on age+/-2 yrs. Conditional logistic regression estimated odds ratios (ORs) for recent HT exposure (any estrogen and/or progestogen within 60 days) and current statin therapy (\geq 90 days continuous exposure) controlling for VTE risk factors, comorbidities, and coronary artery disease.

Results. In a comparison of cases (n=20,359) and matched controls (n=203,590), 9% (n=19,558) had recent HT exposure and 16% (n=36,238) had current/continuous statin exposure. In adjusted models, the OR for any recent HT exposure was 1.51 (95% CI: 1.43, 1.60) compared to no HT exposure. The OR for current statin therapy was 0.88 (95% CI: 0.84, 0.93). For those with HT exposure without statin therapy the OR was 1.53 (95% CI: 1.44, 1.63), for those with HT exposure with statin therapy the OR was 1.25 (95% CI: 1.10, 1.43), and for those exposed to statin therapy without HT exposure the OR was 0.89 (95% CI: 0.85, 0.94), compared those not exposed to either statin or HT. HT with statin therapy had a 18% significantly lower odds ratio than HT without statin therapy (OR=0.82, 95% CI: 0.71, 0.94). High intensity statin therapy showed greater risk reduction.

Conclusion. Statin therapy may reduce VTE risk associated with HT.

INTRODUCTION

Menopause-associated symptoms, such as 'hot flashes', vaginal dryness, disruptions in sleep patterns, and cognitive changes, are common and can affect quality of life.^{1–3} Hormone therapy (HT) is an effective treatment for many of these symptoms.^{4,5} However, concern for venous thromboembolism (VTE), stroke, or myocardial infarction (MI) risk prevents many symptomatic women from receiving HT.^{6–8} HT may double the risk for VTE,^{9–11}although the clinical trials were conducted with oral, conjugated equine estrogen (CEE)^{9,12} and newer studies suggest risk may be lower with other types of estrogen,^{13–17} routes of administration,^{15,17–19} and earlier initiation of therapy.^{20–22}

In the decades since HT trials were conducted, statin therapy has shown efficacy in reducing risk for major cardiovascular events^{23,24} and VTE.^{25,26} but few studies have estimated statin's effect on HT-associated VTE risk. Concomitant HT and statin therapy suggests that the anti-inflammatory and anti-thrombotic effects of statin therapy may mediate risk of adverse cardiovascular events associated with HT.^{27,28} A UK study in post-menopausal women found VTE risk from oral HT exposure for those not on statin therapy was 51% higher and for those on statin therapy was 21% higher than for those not exposed to oral HT.²⁷ Similar reductions have been found for other adverse HT outcomes.²⁸, ^{29, 30}

Studies suggesting statins may reduce excess risk of VTE associated with HT, need validation in the US population because of different formulary, prescribing patterns, and higher VTE incidence. VTE incidence in the UK ranged from 150-175 cases (2017-2019), while US rates were 214 cases per 100,000 person-years (2015-2019).³¹ Also in the past two decades, statin use increased from 16% (2002) to 26% (2017),³² while use of estrogen products (oral, vaginal, and transdermal) in women over 50 decreased from approximately 12.5% (2006) to 9.2% (2015) with larger reductions in oral estrogen products.³³ Thus, this study explored the effect of statin therapy on VTE risk in women 50-64 years of age exposed to exogenous hormones.

METHODS

Dataset and Cohort Selection

A nested case-control study was designed within Optum's de-identified Clinformatics® Data Mart Database that contains claims for approximately 62 million unique enrollees from 2008-2019. Excluding Medicare Advantage subscribers, there are approximately 15 million annual members, a third of whom have continuous enrollment for three or more years. Because VTE incidence is relatively low, Clinformatics® is one of the few US databases containing a sufficient sample size to study VTE risk factors. The database contains information on outpatient and inpatient visits, diagnoses, and filled prescriptions. The age and sex distribution in the database is similar to the US population (within 1-3%), but minorities are slightly underrepresented (13% vs. 19% Hispanic and 10% vs. 14% Black) compared to the US population.³⁴ Also, more members reside in the southern US region (11% higher) than the US population.

The study cohort was limited to women 50-64 years of age with one or more years of continuous enrollment. This age range was selected because of the average age at menopause,³⁵ higher rates of menopausal HT in this range,³³ and the tendency to transition from commercial insurance to Medicare at 65 years. The study focused on statin therapy and HT as part of a larger project on VTE (design details, including ICD and CPT codes, reported elsewhere¹⁵), following The Strengthening of Reporting in Observational studies in Epidemiology (STROBE) guidelines.³⁶

Cases and Controls

Cases were defined as women with a VTE diagnostic code during the observation period followed by one or more prescriptions for an anti-coagulant (excluding heparin flushes), intravascular vena cava filter, or death within 30 days of the VTE diagnosis (index date).¹⁵ Controls were randomly selected and matched to cases by month of index date and age (+/-2 years) at a 10:1 ratio. Women were excluded with less than 12 months of enrollment data prior to index date, an acute or chronic VTE diagnosis or an IVC filter placement in the year prior to the index date, or exposure to an anticoagulant

within the 14 days prior to the index date (anyone with a filled prescription for an anticoagulant during that period).

HT Exposure

HT exposure was defined by a filled prescription for any estrogen and/or progestogen and the duration of the prescription (30 or 90 days). Exposure was evaluated regardless of route (oral/non-oral) or indication (e.g., menopausal HT or contraception). Timing of HT exposure was defined as recent (within 60 days of the index date) or past/none, because previous research indicated VTE risk diminished after 60 days.¹⁵ National Drug Codes (NDCs) for hormones were identified using Red Book³⁷ and/or from a list supplied by the Food and Drug Administration³³ (list published previously¹⁵).

Statin Exposure

Statin exposure was defined by duration and continuity of filled prescriptions. Although the UK study²⁷ defined statin exposure as occurring within 90 days of the index date, here statin exposure was defined as continuous filled prescriptions for at least 90 days prior to and including the index date, because statin trials show effectiveness with longer duration.²⁴ The comparison category was shorter, discontinuous exposures, or no exposure in the past year. Intensity of therapy during most recent 30 days prior to the index date was considered as: 1) high, 2) low/moderate, or 3) none. AHA guidelines³⁸ defined high intensity as atorvastatin \geq 40mg or rosuvastatin \geq 20mg. Lower doses of atorvastatin and rosuvastatin and all other statin exposures were considered low/moderate dose. National Drug Codes (NDCs) from Red Book³⁷ were used to identify statin prescriptions and formulations by intensity of statin therapy (**Appendix**).

Statistical Analysis

Risk for VTE with statin and/or HT exposures was estimated with adjusted odds ratios (ORs) and 95% confidence intervals.³⁹ Because of the matched design, conditional logistic regression models were used.^{17,27,30} Covariates included region of residence, age at index date, history of cancer (except non-melanoma skin cancer;

none/nonmetastatic/metastatic), history of prothrombotic conditions or other types of thrombosis (i.e., superficial thrombophlebitis), and varicose veins within the previous year; and within 30 days of the index date: hospitalization/surgery or trauma. In addition, coronary artery disease, stroke, lipid disorders, and smoking within the past year were included, as they may affect likelihood of prescribing HT or statin therapy. Finally, the Elixhauser set of comorbidities was included to control for general health status.⁴⁰ The Elixhauser index has been validated for predicting mortality and includes chronic conditions such as obesity, liver disease, diabetes, etc.⁴¹ Known VTE risk factors (cancers and hypercoaguable conditions) were removed from the index and used as separate covariates. The final Elixhauser comorbidity index was summed and coded into terciles: 0, 1-2, and 3+ comorbidities.

Models estimated the effects of HT and statin exposure on VTE risk, controlling for covariates. Sensitivity analyses examined the stability of main effects across subsamples with different comorbidity burdens. Because conditional and unconditional analyses yield similar results when few matching criteria are used,⁴² unconditional analyses were used on stratified subsamples to avoid loss of observations. An interaction term in the full sample with a conditional analysis assessed whether effect modification occurred between statin and HT exposures. Intensity of most recent statin exposure also was assessed.

To estimate the combined effect of statin and HT exposure across the observed distribution of risk factors, women were coded into four groups by their HT and statin exposure status. ORs were estimated for HT exposure without statin therapy, HT exposure with statin therapy, and statin therapy without HT exposure with reference to those with neither HT nor statin therapy. A model estimated the effect of statin intensity with subgroups for lower and higher intensity therapy.

RESULTS

Sample Characteristics

There were 22.9 million women identified as having at least one year of continuous enrollment within the Clinformatics® database, of whom 74,600 (0.33%) had a first, acute VTE with 12 months of prior enrollment, and 22,380,610 were eligible controls (no acute VTE diagnoses from 2008-2019) for matching. After study criteria were applied, 20,359 cases remained (definite cases); 54% (n=10,995) were pulmonary emboli (PE) (with or without deep vein thrombosis, DVT), 46% (n=9,364) were DVT without PE, and 6% (n=1,197) died within 30 days following diagnosis. All cases were successfully matched to controls (n=203,590). Women were approximately equally distributed in five-year age intervals and a larger proportion of cases had more comorbidities and VTE risk factors than controls (**Table 1**).

Statin and Hormone Exposures

Recent exposures to any HT occurred in 9% (n=19,558) of the sample (10.5% cases, 8.6% controls). Of those exposures, 76% were menopausal estrogen or estrogenprogestogen combinations (71% oral/29% non-oral), 13% were estrogen-progestin contraceptives, 8% were progesterone only, and 4% were estrogen-testosterone combinations. Those with recent HT exposure tended to be younger (34% unexposed, 43% exposed <55 yrs). For statin therapy, 16% (n=36,238; 18.3% cases, 16.0% controls) of the sample had current/continuous exposure for at least three months before and including the index date, 8% (n=17,569) had shorter or discontinuous exposures, and 76% (n=170,142) had no exposure in the past year. Shorter/intermittent exposure was not significantly different from no exposure (OR=1.05, 95% CI: 0.99, 1.12) but was significantly different from three or more months of current/continuous exposure (OR=1.18, 95% CI: 1.10, 1.25), indicating that the intermittent and no exposure groups could be combined. Those with current/continuous statin exposure tended to be older (29% unexposed, 45% exposed >60), have hyperlipidemia diagnoses (29% unexposed, 86% exposed), or have CAD (4% unexposed, 14% exposed) than those without current/continuous exposure. Among those exposed to

statins, 80% were exposed to low/moderate intensity and 20% were exposed to high intensity in the 30 days prior to the index date.

After adjustment for all covariates, the OR for any recent HT exposure (regardless of statin exposure) was elevated 51% compared to those without recent HT exposure (**Table 2:** OR=1.51, 95% CI: 1.43, 1.60). The OR for current/continuous statin therapy (regardless of HT exposure) was 12% lower than less/no statin therapy (OR=0.88, 95% CI: 0.84, 0.93). There was slightly less reduction with low/moderate intensity (OR=0.90, 95% CI: 0.85, 0.95) and slightly more with high intensity (OR=0.82, 95% CI: 0.75, 0.90) statin therapy compared to those without current statin exposure. Results for HT and statin therapy were consistent across the total sample with and without a conditional analysis, between the total sample and a subsample with above and below median comorbidity burdens (**Table 2**). The one exception was the effect of HT exposure in subsamples with fewer or greater comorbidities. There was no significant interaction between HT and statin therapy on VTE risk.

Patient Groups with HT and/or Statin Exposures

The combined main effects of statin and HT were estimated for the four groups created by HT and statin exposures. As hypothesized, the OR was highest for women exposed to HT without statin therapy compared to the reference group with neither recent HT nor statin exposure (**Table 3**, Model 1). The OR for those with HT exposure but without statin therapy (n=16,350) was 53% elevated (OR=1.53, 95% CI: 1.44, 1.63) over the reference group (n=171,361). The OR for HT exposure combined with statin therapy (n=3,208) was 25% higher (OR=1.25, 95% CI: 1.10, 1.43) than the reference group. A direct comparison between HT with statin therapy and HT without statin therapy showed a 18% significantly lower OR with statin therapy (OR=0.82, 95% CI: 0.71, 0.94). Finally, the lowest risk was for those exposed to statin therapy without HT exposure; the OR was 11% (OR=0.89, 95% CI: 0.85, 0.94) lower than the reference group.

When subgroups exposed to statins were subdivided into low/moderate or high intensity therapy, a larger protective effect was observed with high intensity therapy compared to the reference group without recent HT or statin exposure (**Table 3**, Model 2). ORs were elevated 53% with recent HT exposure without statin (as above) and were elevated 29% with low/moderate statin intensity (OR=1.29, 95% CI: 1.12, 1.49), but were not elevated with high statin intensity (OR=1.06, 95% CI: 0.77, 1.45) compared to those without recent HT and without current statin therapy. A direct comparison between HT without statin therapy and HT with low/moderate statin intensity showed a 16% reduction (OR=0.84, 95% CI: 0.73, 0.98) and comparison to HT with high statin intensity showed a 31% reduction (OR=0.69, 95% CI: 0.50, 0.95). The OR for those without recent HT exposure showed a 9% reduction with low/moderate intensity but a 16% reduction with high intensity statin therapy (OR=0.84, 95% CI: 0.76, 0.92) compared to the reference group without HT and without statin.

DISCUSSION

This is the first study in a US claims database that assessed risk of VTE in women of post-menopausal age that assessed HT and statin exposures. In weighing the benefits of menopausal symptom relief against reported risks of VTE from clinical trials^{6,10} and cohort studies,^{11,17} this study provides insight into additional factors affecting the risk profile of HT users. In this study, results indicated HT-associated VTEs may be reduced with statin therapy. Recent HT exposure elevated risk 53% without statin exposure, but elevated risk 25% when combined with statin therapy (compared to the reference group without HT and without statin exposure) – a significant 18% reduction. Higher intensity statin therapy reduced risk 31% (compared to the reference group) and mitigated HT-associated excess risk, providing evidence of a dose-response effect in the association.

The risk reduction for those with HT and concomitant statin therapy was similar to previous studies. This study and a UK study each showed an almost 20% reduction in HT risk with statin therapy, although the UK study used an earlier time period (1987-2008), broader age range (50-79 years), and focused on oral menopausal HT exposures.²⁷ This study used AHA definitions for statin intensity and found a dose-

response effect, while the UK study used a different definition and did not see further reductions with higher intensity. Similarly, the re-analysis of the HERS cohort, showed VTE risk from HT was 75% greater than placebo (HR=1.75, p=0.04) for those unexposed to statins, but women exposed to both statins and HT had a lower, non-significant elevation in risk compared to placebo (HR=1.34, p=0.45).²⁸

The overall 51% increase in risk for VTE with HT exposure found in this study is consistent with other studies. A large, UK case-control study found any menopausal HT exposure in the past 90 days increased the odds ratio 43%, oral exposures increased the odds ratio 58%, and CEE exposures almost doubled the odds ratio compared to no HT exposure.¹⁷ Clinical trial estimates indicating HT may double the risk for VTE^{9,10} may be higher because of older age of HT initiation and use of oral, CEE.^{15,17} This study therefore affirms and expands previous findings.

In this study, HT risk was slightly higher for those with fewer comorbidities and slightly lower for those with more comorbidities compared to no HT exposure. This difference was likely due to greater exposure to contraceptives (and higher risk estrogen and progestin formulations) in the younger US women with fewer comorbidities.¹⁵ A notable difference between this sample and the UK samples^{17,27} was the number of women in the US sample on higher-risk combined hormone contraceptives.¹⁵ Women over 50 years of age exposed to combined hormonal contraceptives had five to nine times higher risk of VTE compared to those with no hormone exposure.¹⁵

The overall reduction in VTE risk with statin therapy observed in this study (12%) is smaller than estimated in previous observational studies but similar to the reduction found in RCTs. Cohort studies suggest statin exposure may reduce VTE risk by 25%,⁴³ while RCTs indicate a 15% reduction in risk²⁵ and accentuation by intensity of therapy.^{25,26,44,45} Differences between cohort and RCT findings may be attributable to differences in patient populations,⁴⁶ as well as other factors. In this study, statin therapy did not interact with HT, but instead had an independent reduction in VTE that resembled RCT estimates.

Limitations

There are several limitations to this study. Most importantly, this study is a nested casecontrol design in an administrative claims database and contains all inherent limitations of a secondary, observational dataset. Although the study cannot directly prove causality, the time-restricted design offered an unbiased estimation of exposure risk for the population in the base cohort. Possible bias was minimized by employing a strict case definition. While others^{17,27,30,47} included "probable" cases in their analyses, we combined diagnostic claim codes with confirmatory events (i.e., hospitalization, death, or anticoagulant prescription within 30 days of diagnosis) to increase diagnostic accuracy and detection of "definite" cases.⁴⁸ We also adjusted for comorbidities that could potentially confound estimates and controlled for CAD, stroke, and lipid disorders to minimize indication bias.

Other limitations include a limited lookback period, rather than a lifetime medical history, and limited information on patient characteristics. The database contained data on patient age, sex, and region of residence, but lacked data on race/ethnicity, income, educational level, and indications for prescriptions. Race/ethnicity is modestly associated with VTE,^{49,50} but may be mediated by comorbidities, region, and/or socioeconomic status.⁵⁰ In this study, we controlled for comorbidities and region of residence. Socioeconomic status was indirectly controlled for as all patients had private health insurance. The dataset also did not have information on over-the-counter medications, such as aspirin, which may⁵¹ or may not⁵² have an independent protective effect on VTE in this population.

Despite these limitations, medication and diagnostic detail contained in the large administrative claims database allowed for the estimation of effect size for low prevalence exposures and outcomes. This was especially true for estimating risk for those with both hormone and statin exposures. Furthermore, there were sufficient women to make inferences about intensity of statin therapy in VTE reduction.

CONCLUSION

Clinical trials have shown that HT increases risk for VTE and that statin therapy decreases risk for VTE. This study suggests concomitant HT and statin therapy may reduce risk caused by HT. While women who are at higher cardiovascular risk may take statins, and thus may seem unlikely candidates for HT, statin therapy appears to mitigate some of the risk from HT. HT may not be contraindicated in women who are candidates for statin therapy.

REFERENCES

- 1. Twiss JJ, Wegner J, Hunter M, Kelsay M, Rathe-Hart M, Salado W. Perimenopausal symptoms, quality of life, and health behaviors in users and nonusers of hormone therapy. *J Am Acad Nurse Pract*. 2007;19(11):602-613. doi:10.1111/j.1745-7599.2007.00260.x
- 2. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern Med.* 2015;175(4):531-539. doi:10.1001/jamainternmed.2014.8063
- Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause — global prevalence, physiology and implications. *Nat Rev Endocrinol*. 2018;14(4):199-215. doi:10.1038/nrendo.2017.180
- Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. *Cochrane Database Syst Rev.* 2004;2004(4):CD002978. doi:10.1002/14651858.CD002978.pub2
- 5. Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy. *Medicina (Mex)*. 2019;55(10):668. doi:10.3390/medicina55100668
- Cushman M, Kuller LH, Prentice R, et al. Estrogen Plus Progestin and Risk of Venous Thrombosis. *JAMA*. 2004;292(13):1573-1580. doi:10.1001/jama.292.13.1573
- Sprague BL, Trentham-Dietz A, Cronin KA. A Sustained Decline in Postmenopausal Hormone Use: Results From the National Health and Nutrition Examination Survey, 1999–2010. *Obstet Gynecol*. 2012;120(3):595-603. doi:10.1097/AOG.0b013e318265df42
- 8. Lobo RA. Where are we 10 years after the Women's Health Initiative? *J Clin Endocrinol Metab.* 2013;98(5):1771-1780. doi:10.1210/jc.2012-4070
- 9. WHI Trial Investigators. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. *JAMA*. 2004;291(14):1701-1712. doi:10.1001/jama.291.14.1701
- Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *JAMA*. 2002;288(1):49-57. doi:10.1001/jama.288.1.49

- 11. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long □term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev.* 2017;(1). doi:10.1002/14651858.CD004143.pub5
- 12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321-333. doi:10.1001/jama.288.3.321
- 13. Kim JE, Chang JH, Jeong MJ, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. *Sci Rep.* 2020;10(1):20631. doi:10.1038/s41598-020-77534-9
- Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. *J Thromb Haemost*. 2012;10(11):2277-2286. doi:10.1111/j.1538-7836.2012.04919.x
- 15. Weller SC, Davis JW, Porterfield L, Chen L, Wilkinson G. Hormone exposure and venous thromboembolism in commercially insured women aged 50 to 64 years. *Res Pract Thromb Haemost.* 2023;7(3):100135. doi:10.1016/j.rpth.2023.100135
- Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Maras L. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. *Menopause N Y N*. 2016;23(6):593-599. doi:10.1097/GME.000000000000611
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ*. 2019;364:k4810. doi:10.1136/bmj.k4810
- Canonico M, Alhenc-Gelas M, Plu-Bureau G, Olié V, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. *Menopause N Y N*. 2010;17(6):1122-1127. doi:10.1097/gme.0b013e3181e102eb
- 19. Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. *Climacteric J Int Menopause Soc.* 2010;13(5):429-432. doi:10.3109/13697137.2010.507111
- 20. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. *JAMA*. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040

- 21. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. *J Womens Health* 2002. 2006;15(1):35-44. doi:10.1089/jwh.2006.15.35
- 22. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev.* 2015;(3). doi:10.1002/14651858.CD002229.pub4
- 23. Collaborators CTT (CTT). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *The Lancet*. 2012;380(9841):581-590. doi:10.1016/S0140-6736(12)60367-5
- 24. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *The Lancet*. 2016;388(10059):2546. doi:10.1016/S0140-6736(16)31357-5
- 25. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. *Lancet Haematol.* 2017;4(2):e83-e93. doi:10.1016/S2352-3026(16)30184-3
- 26. Glynn RJ, Danielson E, Fonseca FA, et al. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism: the JUPITER Trial. *N Engl J Med.* 2009;360(18):1851-1861. doi:10.1056/NEJMoa0900241
- Fournier JP, Duijnhoven RG, Renoux C, Dell'Aniello S, Klungel OH, Suissa S. Concurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women: a population-based case-control study. *Menopause*. 2014;21(9):1023-1026. doi:10.1097/GME.00000000000279
- 28. Herrington DM, Vittinghoff E, Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). *Circulation*. 2002;105(25):2962-2967. doi:10.1161/01.cir.0000019406.74017.b2
- 29. Koh KK, Schenke WH, Waclawiw MA, Csako G, Cannon RO. Statin Attenuates Increase in C-Reactive Protein During Estrogen Replacement Therapy in Postmenopausal Women. *Circulation*. 2002;105(13):1531-1533. doi:10.1161/01.CIR.0000013837.81710.DA
- Berglind IA, Andersen M, Citarella A, Linder M, Sundström A, Kieler H. Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins. *Menopause N Y N*. 2015;22(4):369-376. doi:10.1097/GME.00000000000345
- Weller SC, Porterfield L, Davis J, Wilkinson GS, Chen L, Baillargeon J. Incidence of venous thrombotic events and events of special interest in a retrospective cohort of commercially insured US patients. *BMJ Open*. 2022;12(2):e054669. doi:10.1136/bmjopen-2021-054669

- Salami JA, Warraich H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. *JAMA Cardiol*. 2017;2(1):56. doi:10.1001/jamacardio.2016.4700
- Weissfeld JL, Liu W, Woods C, et al. Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance. *Menopause*. 2018;25(6):611-614. doi:10.1097/GME.00000000001054
- 34. U.S. Census Bureau QuickFacts: United States. Accessed July 28, 2023. https://www.census.gov/quickfacts/fact/table/US/PST045222
- 35. Appiah D, Nwabuo CC, Ebong IA, Wellons MF, Winters SJ. Trends in Age at Natural Menopause and Reproductive Life Span Among US Women, 1959-2018. *JAMA*. 2021;325(13):1328-1330. doi:10.1001/jama.2021.0278
- 36. Cuschieri S. The STROBE guidelines. *Saudi J Anaesth*. 2019;13(Suppl 1):S31-S34. doi:10.4103/sja.SJA_543_18
- 37. Micromedex RED BOOK Micromedex RED BOOK. Published March 31, 2022. Accessed May 22, 2022. https://www.ibm.com/products/micromedex-red-book
- Newman Connie B., Preiss David, Tobert Jonathan A., et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. *Arterioscler Thromb Vasc Biol.* 2019;39(2):e38-e81. doi:10.1161/ATV.00000000000073
- 39. Ward JH. Hierarchical Grouping to Optimize an Objective Function. *J Am Stat Assoc.* 1963;58(301):236-244. doi:10.1080/01621459.1963.10500845
- 40. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care*. 2005;43(11):1130-1139. doi:10.1097/01.mlr.0000182534.19832.83
- 41. Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. *Med Care*. 2004;42(4):355-360. doi:10.1097/01.mlr.0000118861.56848.ee
- 42. Kuo CL, Duan Y, Grady J. Unconditional or Conditional Logistic Regression Model for Age-Matched Case–Control Data? *Front Public Health*. 2018;6:57. doi:10.3389/fpubh.2018.00057
- 43. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. *Lancet Haematol.* 2017;4(2):e83-e93. doi:10.1016/S2352-3026(16)30184-3

- 44. Tagalakis V, Eberg M, Kahn S, Azoulay L. Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study. *Thromb Haemost.* 2016;115(6):1220-1228. doi:10.1160/TH15-10-0775
- 45. Joseph P, Glynn R, Lonn E, et al. Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. *Cardiovasc Res.* 2022;118(3):897-903. doi:10.1093/cvr/cvab078
- 46. Miksza JK, Zaccardi F, Kunutsor SK, Seidu S, Davies MJ, Khunti K. Statins and risk of thromboembolism: A meta-regression to disentangle the efficacy-to-effectiveness gap using observational and trial evidence. *Nutr Metab Cardiovasc Dis NMCD*. 2019;29(10):1023-1029. doi:10.1016/j.numecd.2019.06.022
- 47. Renoux C, Dell'ANIELLO S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. *J Thromb Haemost*. 2010;8(5):979-986. doi:10.1111/j.1538-7836.2010.03839.x
- 48. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. *J Thromb Haemost*. 2005;3(8):1611-1617. doi:10.1111/j.1538-7836.2005.01415.x
- 49. Goldhaber SZ. Race and Venous Thromboembolism. *Circulation*. 2014;129(14):1463-1465. doi:10.1161/CIRCULATIONAHA.114.008799
- 50. Zakai NA, McClure LA, Judd SE, et al. Racial and Regional Differences in Venous Thromboembolism in the United States in 3 Cohorts. *Circulation*. 2014;129(14):1502-1509. doi:10.1161/CIRCULATIONAHA.113.006472
- 51. Grady D, Wenger NK, Herrington D, et al. Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study. *Ann Intern Med.* 2000;132(9):689-696. doi:10.7326/0003-4819-132-9-200005020-00002
- 52. Ridker PM, Cook NR, Lee IM, et al. A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women. *N Engl J Med.* 2005;352(13):1293-1304. doi:10.1056/NEJMoa050613